{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-157521","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2024-06-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.428399+00:00","generated_at":"2026-06-01T05:36:13.364900+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"4D Molecular Therapeutics enters $250M ATM equity distribution agreement with Leerink Partners","bullets":["Company enters Sales Agreement to sell up to $250M common stock via at-the-market offering through Leerink Partners.","Agent compensation up to 3.0% of gross proceeds; sales made on Nasdaq via Rule 415(a)(4).","Offering registered under existing S-3 filed Feb 2024; prospectus supplement filed June 7, 2024.","No minimum sales obligation; company may terminate at any time upon prior notice.","Proceeds for general corporate purposes; no escrow arrangement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-157521","json":"https://secwatch.observer/filing/0001193125-24-157521.json","markdown":"https://secwatch.observer/filing/0001193125-24-157521.md","text":"https://secwatch.observer/filing/0001193125-24-157521.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000119312524157521/0001193125-24-157521-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000119312524157521/d835355d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:36:13.364900+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}